Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide modified sustained-release formulations versus Phase 3 formulation in healthy volunteers
NL-OMON34034Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of taspoglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Roche. Primary endpoints: Reduction of initial taspoglutide Cmax, Pharmacodynamics and 2 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34034.